Immune Pharmaceuticals Inc. (Nasdaq: IMNP) to Ring The Nasdaq Stock Market Closing Bell
IMNP & ICOTF go hand in hand! ICOTF has HUGE UPSIDE POTENTIAL!
Immune Pharmaceuticals Inc. (Nasdaq:IMNP), a clinical stage bio-pharmaceutical company with a first-in-class monoclonal antibody, bertilimumab, for the treatment of auto-immune diseases, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Dr. Daniel Teper, Chief Executive Officer will ring the Closing Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Tuesday, May 26, 2015 – 3:45 p.m. to 4:00 p.m. ET
Immune Pharmaceuticals Media Contact:
Anna Baran
(646) 937-1941
Anna.baran@immunepharma.com
About Immune Pharmaceuticals Inc. (Nasdaq:IMNP):
Immune Pharmaceuticals Inc. applies a personalized approach to treating and developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company's lead product candidate, bertilimumab, is in clinical development for moderate to severe ulcerative colitis and Crohn's disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition. Immune licensed worldwide rights for systemic indications of bertilimumab from iCo Therapeutics (TSX:ICO) (OTCQX:ICOTF) in June 2011, while iCo retained rights to all ophthalmic indications. iCo originally licensed the exclusive world-wide rights to bertilimumab in 2006 from MedImmune, the Global Research and Development arm of AstraZeneca. Immune's pipeline also includes NanomAbs, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics, and AmiKet™, a Neuropathic Pain drug candidate ready for a Phase III clinical trial. AmiKet has received Orphan Drug Designation in the U.S. for Post-Herpetic Neuralgia.
LET'S ALL MAKE SOME $$$$$$$
